About Durin Technologies
Durin Technologies is a Healthcare company based in Camden (United States) founded in 2010 by Benjamin Belinka and Robert Nagele. Durin Technologies has raised $8.05 million across 3 funding rounds from investors including Breakthrough Diagnostics. Durin Technologies offers products and services including Duritect-AD™ and Duritect-PD™. Its focus areas include Life Sciences, Neurology, In-Vitro Diagnostics and Neurodegenerative. Its legal entity is DURIN TECHNOLOGIES, INC.
Company details
Developer of the diagnostic test for neurodegenerative diseases. The test is based on the detection of disease-specific autoantibodies as blood biomarkers associated with Alzheimers and Parkinsons disease.
- Headquarters Camden, United States
- Founders Benjamin Belinka, Robert Nagele
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website durintechnologies.com
- Social LinkedIn
- Legal Name Durin Technologies, Inc.
- Total Equity Funding$8.05M (USD)
in 3 rounds
- Latest Funding Round$3.5M (USD), Debt – Conventional
Oct 2023
Products & Services of Durin Technologies
Durin Technologies offers a comprehensive portfolio of products and services, including Duritect-AD™ and Duritect-PD™.
Blood test for early assessment of Alzheimer's disease risk.
Blood test for early assessment of Parkinson's disease risk.
Funding Insights of Durin Technologies
Durin Technologies has successfully raised a total of $8.05M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $3.5 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.05M
- Total Rounds 3
- Last Round Debt – Conventional — $3.5M
- First Round $3.5M
(Dec 2019)
- Investors Count 1
All 3 funding rounds of Durin Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2023 | $3.5M | Debt – Conventional | – | – | |
| Dec 2022 | $4.55M | Series B | – | – | – |
| Dec 2019 | $3.5M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Durin Technologies
Durin Technologies has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Breakthrough Diagnostics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investor details for Durin Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Durin Technologies
4 people are tracked at Durin Technologies (4 in leadership).
| Name | Role | Group |
|---|---|---|
Benjamin Belinka | Co-Founder | Leadership |
Robert Nagele | Co-Founder | Leadership |
Mert Sahin, PhD | Chief Executive Officer | Leadership |
Dennis Hutchison | Chief Strategy And Commercial Officer | Leadership |
Complete people profiles for Durin Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Durin Technologies
3 dated milestones of Durin Technologies across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Durin Technologies is founded.
- Funding First funding round of $3.5M.
- Funding Latest funding round, Debt – Conventional, of $3.5M.
Top companies in Neurology
3 companies that operate in the same segment as Durin Technologies (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Durin Technologies
Complete news archive for Durin Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Durin Technologies
Durin Technologies was founded in 2010 and raised its 1st funding round 9 years after it was founded.
Durin Technologies is headquartered in Camden, United States.
Durin Technologies is a funded company, having raised a total of $8.05M across 3 funding rounds to date. The company's 1st funding round was a Series A of $3.5M, raised on Dec 2019.
Developer of the diagnostic test for neurodegenerative diseases. The test is based on the detection of disease-specific autoantibodies as blood biomarkers associated with Alzheimers and Parkinsons disease.
Durin Technologies offers Duritect-AD™ and Duritect-PD™.
Durin Technologies has 1 investor. Key investors include Breakthrough Diagnostics.
Durin Technologies operates through Durin Technologies, Inc..